Literature DB >> 21179054

Hematology: Bortezomib and dexamethasone induction for multiple myeloma.

Jacob Laubach, Paul Richardson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21179054     DOI： 10.1038/nrclinonc.2010.206

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  7 in total

1.  Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.

Authors:  D O'Shea; C Giles; E Terpos; J Perz; M Politou; V Sana; K Naresh; I Lampert; D Samson; S Narat; E Kanfer; E Olavarria; J F Apperley; A Rahemtulla
Journal:  Bone Marrow Transplant       Date:  2006-04       Impact factor: 5.483

2.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Authors:  Paul G Richardson; Edie Weller; Sagar Lonial; Andrzej J Jakubowiak; Sundar Jagannath; Noopur S Raje; David E Avigan; Wanling Xie; Irene M Ghobrial; Robert L Schlossman; Amitabha Mazumder; Nikhil C Munshi; David H Vesole; Robin Joyce; Jonathan L Kaufman; Deborah Doss; Diane L Warren; Laura E Lunde; Sarah Kaster; Carol Delaney; Teru Hideshima; Constantine S Mitsiades; Robert Knight; Dixie-Lee Esseltine; Kenneth C Anderson
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

3.  Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.

Authors:  Annemiek Broyl; Sophie L Corthals; Joost Lm Jongen; Bronno van der Holt; Rowan Kuiper; Yvonne de Knegt; Mark van Duin; Laila el Jarari; Uta Bertsch; Henk M Lokhorst; Brian G Durie; Hartmut Goldschmidt; Pieter Sonneveld
Journal:  Lancet Oncol       Date:  2010-09-21       Impact factor: 41.316

4.  Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.

Authors:  I Majolino; M Vignetti; G Meloni; M L Vegna; R Scimè; S Tringali; G Amaddii; P Coser; M Tribalto; R Raimondi; C Bergonzi; M R Sajeva; S Sica; F Ferrando; G Messina; F Mandelli
Journal:  Haematologica       Date:  1999-09       Impact factor: 9.941

5.  Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

Authors:  Jean-Luc Harousseau; Michel Attal; Hervé Avet-Loiseau; Gerald Marit; Denis Caillot; Mohamad Mohty; Pascal Lenain; Cyrille Hulin; Thierry Facon; Philippe Casassus; Mauricette Michallet; Hervé Maisonneuve; Lotfi Benboubker; Frédéric Maloisel; Marie-Odile Petillon; Iain Webb; Claire Mathiot; Philippe Moreau
Journal:  J Clin Oncol       Date:  2010-09-07       Impact factor: 44.544

6.  CR represents an early index of potential long survival in multiple myeloma.

Authors:  M Wang; K Delasalle; L Feng; S Thomas; S Giralt; M Qazilbash; B Handy; J J Lee; R Alexanian
Journal:  Bone Marrow Transplant       Date:  2009-07-27       Impact factor: 5.483

7.  Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.

Authors:  Juan José Lahuerta; Maria Victoria Mateos; Joaquin Martínez-López; Laura Rosiñol; Anna Sureda; Javier de la Rubia; José García-Laraña; Rafael Martínez-Martínez; Miguel T Hernández-García; Dolores Carrera; Joan Besalduch; Felipe de Arriba; José María Ribera; Lourdes Escoda; Belén Hernández-Ruiz; Javier García-Frade; Concepción Rivas-González; Adrían Alegre; Joan Bladé; Jesús F San Miguel
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544
  7 in total
  2 in total

Review 1.  Hematology in 2010: New therapies and standard of care in oncology.

Authors:  Vincent T DeVita; George P Canellos
Journal:  Nat Rev Clin Oncol       Date:  2011-02       Impact factor: 66.675

2.  The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.

Authors:  Katarina Uttervall; Adil D Duru; Johan Lund; Johan Liwing; Gösta Gahrton; Erik Holmberg; Johan Aschan; Evren Alici; Hareth Nahi
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.